Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/leu.2016.296 http://scihub22266oqcxt.onion/10.1038/leu.2016.296 C5382134!5382134!27773931     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27773931&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Leukemia 2017 ; 31 (4): 853-60 Nephropedia Template TP {{tp|p=27773931|t=2017. The LIN28B/let-7 axis is a novel therapeutic pathway in Multiple Myeloma |pdf=|usr=}}{{27773931}} gab.com Text The LIN28B/let-7 axis is a novel therapeutic pathway in Multiple Myeloma JO: Leukemia http://www.kidney.de/pget.php?&tw=1&pmid=27773931 #FOAvip MYC is a major oncogenic driver of Multiple Myeloma (MM) and yet almost no therapeutic agents exist that target MYC in MM. Here we report that the let-7 biogenesis inhibitor LIN28B correlates with MYC expression in MM and is associated with adverse outcome. We also demonstrate that the LIN28B/let-7 axis modulates the expression of MYC, itself a let-7 target. Further, perturbation of the axis regulates the proliferation of MM cells in vivo in a xenograft tumor model. RNA sequencing and gene set enrichment analyses of CRISPR-engineered cells further suggest that the LIN28/let-7 axis regulates MYC and cell cycle pathways in MM. We provide proof-of-principle for therapeutic regulation of MYC through let-7 with an LNA-GapmeR containing a let-7b mimic in vivo, demonstrating that high levels of let-7 expression repress tumor growth by regulating MYC expression. These findings reveal a novel mechanism of therapeutic targeting of MYC through the LIN28B/let-7 axis in MM that may impact other MYC dependent cancers as well. Twit Text FOAVip The LIN28B/let-7 axis is a novel therapeutic pathway in Multiple Myeloma ????Leukemia http://www.kidney.de/pget.php?&tw=1&pmid=27773931 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27773931 #FOAvip English Wikipedia <ref>{{Cite pmid|27773931}}</ref> The LIN28B/let-7 axis is a novel therapeutic pathway in Multiple Myeloma #MMPMID27773931 Manier S; Powers JT; Sacco A; Glavey SV; Huynh D; Reagan MR; Salem KZ; Moschetta M; Shi J; Mishima Y; Roche-Lestienne C; Leleu X; Roccaro AM; Daley GQ; Ghobrial IM Leukemia 2017[Apr]; 31 (4): 853-60 PMID27773931show ga MYC is a major oncogenic driver of Multiple Myeloma (MM) and yet almost no therapeutic agents exist that target MYC in MM. Here we report that the let-7 biogenesis inhibitor LIN28B correlates with MYC expression in MM and is associated with adverse outcome. We also demonstrate that the LIN28B/let-7 axis modulates the expression of MYC, itself a let-7 target. Further, perturbation of the axis regulates the proliferation of MM cells in vivo in a xenograft tumor model. RNA sequencing and gene set enrichment analyses of CRISPR-engineered cells further suggest that the LIN28/let-7 axis regulates MYC and cell cycle pathways in MM. We provide proof-of-principle for therapeutic regulation of MYC through let-7 with an LNA-GapmeR containing a let-7b mimic in vivo, demonstrating that high levels of let-7 expression repress tumor growth by regulating MYC expression. These findings reveal a novel mechanism of therapeutic targeting of MYC through the LIN28B/let-7 axis in MM that may impact other MYC dependent cancers as well. äThe LIN28B/let-7 axis is a novel therapeutic pathway in Multiple Myelo(epmc).pdf DeepDyve Pubget Overpricing